ArticleHaematologica2020
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 3 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Intracranial manifestations of adult Rosai-Dorfman disease: a systematic review and IPD meta-analysis of 327 cases.Acta neurochirurgica · 2025Pooled it
- A meta-analysis of cases of Rosai Dorfman disease reported on the African continent and a description of two cases from a tertiary academic hospital in Johannesburg, South Africa.The Pan African medical journal · 2023Pooled it
- Rosai-Dorfman-Destombes disease of the nervous system: a systematic literature review.Orphanet journal of rare diseases · 2022Pooled it
- Multifocal osseous and cutaneous Rosai-Dorfman-Destombes disease presenting as an aggressive intramedullary femoral lesion.Radiology case reports · 2026Article
- [IgG4-related disease presenting with involvement of the eyes, pituitary gland and nervous system: A case report].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Unusual progression of Rosai-Dorfman disease in a pediatric patient.Radiology case reports · 2026Article
- Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.European journal of haematology · 2026Article
- Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease.Blood advances · 2026Article
- Pediatric Rosai-Dorfman-Destombes Disease: From Isolated Cervical Lymphadenopathy to Multisystem Disease.Cureus · 2026Article
- Rosai-Dorfman disease presenting as isolated cervical lymphadenopathy in a young adult: A case report.Radiology case reports · 2026Article
- Hyperattenuation on non-enhanced CT and T2 hypointensity: an imaging pattern frequently associated with fibrous or smooth muscle-rich abdominal and pelvic lesions.Abdominal radiology (New York) · 2026Review
- Rosai-Dorfman disease withOxford medical case reports · 2026Article
- Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children.Clinical case reports · 2026Article
- Rosai-Dorfman disease mimicking IgG4-related disease.Wiener medizinische Wochenschrift (1946) · 2026Article
- RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Cancer cell · 2026Article
- The Value of High-Frequency Ultrasound in the Evaluation of Cutaneous Rosai-Dorfman Disease: A Case Series and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Rosai-Dorfman disease mimicking testicular malignancy in a patient with marginal zone lymphoma of the lung.BMJ case reports · 2026Article
- Clinicopathological insights into ophthalmic Rosai-Dorfman disease: A 15-year retrospective analysis.Indian journal of ophthalmology · 2026Article
- Diffuse Large B-Cell Lymphoma Presenting in a Background of Rosai-Dorfman Disease.Case reports in hematology · 2026Article
- Fine-Needle Aspiration as a Key Diagnostic Tool in Pediatric Rosai-Dorfman Disease: A Case Report of a 12-Year-Old Male.International medical case reports journal · 2026Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Rosai-Dorfman disease is a rare subtype of non-Langerhans cell histiocytosis. With the last major report published in 1990, there is a paucity of contemporary data on this disease. Our objective was to report the clinicopathological features, treatments and outcomes of patients seen at a tertiary referral center. Sixty-four patients with histopathological diagnosis of Rosai-Dorfman disease were identified from 1994 to 2017 (median age 50 years; range, 2-79). The median duration from symptom onset to diagnosis was seven months (range, 0-128), which was also reflected in the number of biopsies required to establish the diagnosis (median 2; range, 1-6). The most common presentation was subcutaneous masses (40%). Of the 64 patients, 8% had classical (nodal only) and 92% had extra-nodal disease (67% extra-nodal only). The most common organs involved were skin and subcutaneous tissue (52%), followed by lymph nodes (33%). Three patients had an overlap with Erdheim-Chester disease, which had not been described before. Two of these were found to have MAP2K1 mutations. Commonly utilized first line treatments were surgical excision (38%) and systemic corticosteroids (27%). Corticosteroids led to a response in 56% of the cases. Of those treated initially, 15 (30%) patients developed recurrent disease. The most commonly used systemic agent was cladribine (n=6), with 67% overall response rate. Our study demonstrates that Rosai-Dorfman disease has diverse clinical manifestations and outcomes. While this disease has been historically considered a benign entity, a subset of patients endures an aggressive course necessitating the use of systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.